Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Epithelial High Grade Serous Ovarian Cancer”

64 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 64 results

Not applicableEnded earlyNCT03922776
What this trial is testing

Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Ovarian Cancer

Who this might be right for
Ovarian Cancer Stage IIICFallopian Tube Cancer Stage IIICFallopian Tube Cancer Stage IV+1 more
Centre Oscar Lambret 36
Testing effectiveness (Phase 2)Study completedNCT03759600
What this trial is testing

Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Takeda 20
Early research (Phase 1)Ended earlyNCT05274451
What this trial is testing

Investigate LYL797 in Adults With Solid Tumors

Who this might be right for
Triple Negative Breast CancerTNBC - Triple-Negative Breast CancerNon-small Cell Lung Cancer+20 more
Lyell Immunopharma, Inc. 57
Not applicableNot Yet RecruitingNCT07687602
What this trial is testing

Evaluate Adverse Events and Change in Disease Activity of Mirvetuximab Soravtansine-gynx in Adults With Folate Receptor-Alpha Positive, Platinum-Resistant Ovarian Cancer in a Real-World Setting

Who this might be right for
Folate Receptor-Alpha Positive Platinum-Resistant High-Grade Serous Epithelial Ovarian CancerFolate Receptor-Alpha Positive Platinum-Resistant Fallopian Tube CancerFolate Receptor-Alpha Positive Platinum-Resistant Primary Peritoneal Cancer
AbbVie
Testing effectiveness (Phase 2)Active Not RecruitingNCT04739800
What this trial is testing

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Who this might be right for
Fallopian Tube Mucinous AdenocarcinomaOvarian Seromucinous CarcinomaPlatinum-Refractory Fallopian Tube Carcinoma+47 more
National Cancer Institute (NCI) 120
Testing effectiveness (Phase 2)WithdrawnNCT06393751
What this trial is testing

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Who this might be right for
Platinum-Refractory Fallopian Tube CarcinomaPlatinum-Refractory Ovarian CarcinomaPlatinum-Refractory Primary Peritoneal Carcinoma+20 more
National Cancer Institute (NCI)
Not applicableLooking for participantsNCT07556562
What this trial is testing

Early Diagnosis of High-grade Serous Epithelial Ovarian Cancer Through the Analysis of DNA Derived From Pap Test Smear.

Who this might be right for
Germline Mutations
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 260
Testing effectiveness (Phase 2)Study completedNCT02354586
What this trial is testing

Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Who this might be right for
Ovarian NeoplasmsOvarian Cancer
Tesaro, Inc. 463
Testing effectiveness (Phase 2)Study completedNCT03648489
What this trial is testing

Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

Who this might be right for
Ovarian CancerOvarian NeoplasmsOvarian Carcinosarcoma+7 more
Imperial College London 134
Testing effectiveness (Phase 2)Active Not RecruitingNCT02834013
What this trial is testing

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Who this might be right for
Acinar Cell CarcinomaAdenoid Cystic CarcinomaAdrenal Cortical Carcinoma+91 more
National Cancer Institute (NCI) 798
Early research (Phase 1)Ended earlyNCT05827614
What this trial is testing

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications

Who this might be right for
Triple Negative Breast Cancer (TNBC)High Grade Serous Ovarian CarcinomaHigh Grade Endometrial Carcinoma+9 more
Boundless Bio, Inc. 85
Not applicableStudy completedNCT04823871
What this trial is testing

Early Detection of High Grade Ovarian Cancer Using Uterine Lavage EHUD Study and Duplex Sequencing

Who this might be right for
Ovarian Epithelial CancerCarcinoma in SituOvarian Cancer
Paul Speiser, Prof.MD, 406
Early research (Phase 1)Study completedNCT02898207
What this trial is testing

Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

Who this might be right for
Metastatic High Grade Fallopian Tube Serous AdenocarcinomaMetastatic Malignant Solid NeoplasmMetastatic Primary Peritoneal Serous Adenocarcinoma+16 more
National Cancer Institute (NCI) 28
Testing effectiveness (Phase 2)Ended earlyNCT05243524
What this trial is testing

Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer

Who this might be right for
Platinum-resistant Epithelial Ovarian Cancer
ImmunoVaccine Technologies, Inc. (IMV Inc.) 16
Early research (Phase 1)Looking for participantsNCT04389632
What this trial is testing

Sigvotatug Vedotin in Advanced Solid Tumors

Who this might be right for
Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckHER2 Negative Breast Neoplasms+9 more
Seagen, a wholly owned subsidiary of Pfizer 1,006
Not applicableEnded earlyNCT05891197
What this trial is testing

A Biomarker Screening Protocol for Participants With Solid Tumors

Who this might be right for
Triple Negative Breast CancerNon-small Cell Lung CancerNon Small Cell Lung Cancer+19 more
Lyell Immunopharma, Inc. 10
Early research (Phase 1)Ended earlyNCT04099277
What this trial is testing

LY3435151 in Participants With Solid Tumors

Who this might be right for
Solid TumorTriple-negative Breast CancerGastric Adenocarcinoma+6 more
Eli Lilly and Company 2
Testing effectiveness (Phase 2)Looking for participantsNCT05551507
What this trial is testing

IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer

Who this might be right for
Platinum-resistant Ovarian Cancer
InxMed (Shanghai) Co., Ltd. 150
Testing effectiveness (Phase 2)Looking for participantsNCT05902988
What this trial is testing

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

Who this might be right for
Advanced Solid TumorHigh Grade Serous Adenocarcinoma of OvarySquamous Non-small-cell Lung Cancer+7 more
Volastra Therapeutics, Inc. 200
Testing effectiveness (Phase 2)Ended earlyNCT02012192
What this trial is testing

GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer

Who this might be right for
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Medical University Innsbruck 133
Next Page
69